Kilitch Drugs (India) Limited has informed the Exchange that Board of Directors at its meeting held on July 09, 2025, has decided to issue equity shares on rights basis in the ratio of 2 : 23, i.e 2 Equity Shares for every 23 Equity Shares held. Issue Price is Rs. 357 per share.
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.9 pts more than Nifty Microcap 250 and 5.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kilitch Drugs (India) Limited's board, at its meeting on July 9, 2025, approved a rights issue of 13,98,463 fully paid-up equity shares at Rs. 357 per share. The entitlement ratio is 2 equity shares for every 23 shares held by eligible shareholders. The issue price includes a premium of Rs. 347 per share over the face value of Rs. 10. The record date to determine eligible shareholders is July 15, 2025. If fully subscribed, the company's outstanding shares will rise from about 1.61 crore to 1.75 crore. The rights entitlement is renounceable, and the issue period will be announced separately.
Existing shareholders will get a chance to buy additional shares at a fixed price, which will dilute their holding if they don't participate. The stock may see short-term pressure around the record date, and the actual market reaction will depend on how the issue price of Rs. 357 compares to the prevailing market price.